Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps

Developmental Medicine and Child Neurology
Teresa Gidaro, Laurent Servais

Abstract

Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11 000 newborn infants. The most severe and most common form, type 1 SMA, is associated with early mortality in most cases and severe disability in survivors. Nusinersen, an antisense oligonucleotide, promotes production of full-length protein from the pseudogene SMN2. Nusinersen treatment prolongs survival of patients with type 1 SMA and allows motor milestone acquisition. Patients with type 2 SMA also show progress on different motor scales after nusinersen treatment. Nusinersen was recently approved by the European Medicines Agency and the US Food and Drug Administration; it is now reimbursed in several European countries and in the USA. In Australia, the transition from expanded access programme to commercial availability is coming soon. In New Zealand, an expanded access programme is opened, and in Canada price negotiation for the treatment is in progress. In this review we exemplify the clinical benefit of nusinersen in subgroups of patients with SMA. Nusinersen represents the first efficacious marked approved drug in type 1 and type 2 SMA. Different knowledge gaps, such as results in olde...Continue Reading

References

Mar 29, 2008·American Journal of Human Genetics·Yimin HuaAdrian R Krainer
Dec 22, 2011·Human Molecular Genetics·Paul N PorenskyArthur H M Burghes
Jul 20, 2012·The Journal of Pediatrics·Michelle A FarrarMatthew C Kiernan
Dec 12, 2012·Trends in Molecular Medicine·Gillian Hamilton, Thomas H Gillingwater
Oct 31, 2015·Neurologic Clinics·Stephen J Kolb, John T Kissel
May 6, 2016·Orphanet Journal of Rare Diseases·Constanze KlugKlaus H Nagels
Apr 5, 2017·American Journal of Medical Genetics. Part a·Felicity K BoardmanFrances E Griffiths
Jul 6, 2017·Orphanet Journal of Rare Diseases·Ingrid E C VerhaartHanns Lochmüller
Nov 2, 2017·The New England Journal of Medicine·Jerry R MendellBrian K Kaspar
Nov 2, 2017·The New England Journal of Medicine·Richard S FinkelUNKNOWN ENDEAR Study Group
Nov 15, 2017·Neuromuscular Disorders : NMD·Sonia MessinaUNKNOWN Italian EAP working Group
Jan 25, 2018·Muscle & Nerve·Anthony P GeraciAdam Evans
Feb 15, 2018·The New England Journal of Medicine·Eugenio MercuriUNKNOWN CHERISH Study Group
Mar 20, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·Michelle A FarrarMonique M Ryan
Apr 25, 2018·Journal of Neuromuscular Diseases·Astrid PechmannJanbernd Kirschner
Aug 31, 2018·Neurology·Karolina Aragon-GawinskaLaurent Servais

❮ Previous
Next ❯

Citations

Jun 22, 2019·Expert Review of Clinical Pharmacology·Federica RicciTiziana Mongini
Dec 28, 2019·Developmental Medicine and Child Neurology·Martin Smith
Jan 25, 2020·Expert Opinion on Pharmacotherapy·Sithara Ramdas, Laurent Servais
Nov 7, 2019·Biochemistry. Biokhimii︠a︡·K R ValetdinovaS M Zakian
Sep 26, 2020·Chemical Society Reviews·Samantha M MeyerMatthew D Disney
Mar 21, 2019·Expert Opinion on Pharmacotherapy·Markus Riessland
Apr 10, 2019·Developmental Medicine and Child Neurology·Laurent Servais
Jan 11, 2020·Frontiers in Genetics·Yiming LinXinwen Huang
Apr 20, 2020·Advances in Therapy·Moran LavieIsrael Amirav
Jun 23, 2019·Annals of Neurology·Marika PaneUNKNOWN Italian Expanded Access Program Working Group
Jul 30, 2020·Genetic Testing and Molecular Biomarkers·Busranur CavdarliEmriye Ferda Percin
Oct 8, 2020·Nucleic Acid Therapeutics·Suxiang ChenRakesh N Veedu
Oct 29, 2020·Pediatric Pulmonology·Moran LavieIsrael Amirav
Jul 28, 2019·Journal of Voice : Official Journal of the Voice Foundation·Kathleen WermkeJohannes Wirbelauer
Oct 13, 2019·Early Human Development·Eduardo F Tizzano
Jan 28, 2021·International Journal of Molecular Sciences·Tatyana P MakalishAnatoly V Kubyshkin
Dec 29, 2019·Neuromuscular Disorders : NMD·Tamara DangouloffUNKNOWN NBS SMA Study Group
Dec 19, 2020·The Journal of Biological Chemistry·Aline Umuhire Juru, Amanda E Hargrove
Feb 8, 2021·Developmental Medicine and Child Neurology·Mette van KruijsbergenMarijke C Kars
Jan 26, 2021·Therapeutic Advances in Neurological Disorders·Tai-Heng Chen
Feb 25, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stacy A RudnickiJohn W Day
Mar 23, 2021·Expert Opinion on Investigational Drugs·Laurent ServaisMaryam Oskoui
Mar 24, 2021·Neuromuscular Disorders : NMD·Nicole GussetMencía de Lemus
Mar 31, 2021·Obstetrical & Gynecological Survey·Maeve K HopkinsJeffrey A Kuller
Apr 25, 2021·Seminars in Pediatric Neurology·Stefan NicolauJerry R Mendell
Sep 4, 2021·Neurology. Clinical Practice·Tina DuongJohn W Day
Sep 14, 2021·Current Pharmaceutical Design·Mathilde BeaufilsIsabelle Marty
Dec 19, 2021·Pediatric Pulmonology·Moran LavieIsrael Amirav

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cajal Bodies & Gems

Cajal bodies or coiled bodies are dense foci of coilin protein. Gemini of Cajal bodies, or gems, are microscopically similar to Cajal bodies. It is believed that Cajal bodies play important roles in RNA processing while gems assist the Cajal bodies. Find the latest research on Cajal bodies and gems here.

© 2022 Meta ULC. All rights reserved